{
    "root": "3501779a-87ab-7dab-e063-6294a90a8a0e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metformin Hydrochloride",
    "value": "20250513",
    "ingredients": [
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "HYPROMELLOSE 2208 (100000 MPA.S)",
            "code": "VM7F0B23ZI"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "AMMONIO METHACRYLATE COPOLYMER TYPE A",
            "code": "8GQS4E66YY"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "metformin hydrochloride extended-release tablet indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus .",
    "contraindications": "starting dose : 500 mg orally daily evening meal ( 2.1 ) increase dose increments 500 mg every 1 2 weeks , maximum 2,000 mg daily evening meal . ( 2.1 ) patients receiving metformin hydrochloride ( hcl ) tablets may switched metformin hydrochloride extended-release tablets daily total daily dose , 2,000 mg daily . ( 2.1 ) swallow metformin hydrochloride extended-release tablets whole never crush , cut chew . ( 2.1 ) renal impairment : prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) . ( 2.2 ) patients egfr 30 ml/minute/1.73 2 . initiation recommended patients egfr 30 45 ml/minute/1.73 2 . assess risk/benefit continuing metformin hydrochloride extended-release tablets egfr falls 45 ml/minute/1.73 2 . discontinue egfr falls 30 ml/minute/1.73 2 . discontinuation iodinated contrast imaging procedures : metformin hydrochloride extended-release tablets may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.3 )",
    "warningsAndPrecautions": "metformin hydrochloride extended-release tablets , usp - 500 mg available blue colored oval shaped biconvex , film-coated , tablets debossed ‘ m500 ’ one face plain face approximate dimension 16.20 mm length , 8.20 mm width 7.20 mm thickness . supplied follows : bottle 60 ’ ndc 42571-333-60 bottle 90 ’ ndc 42571-333-90 bottle 100 ’ ndc 42571-333-01 bottle 500 ’ ndc 42571-333-05 metformin hydrochloride extended-release tablets , usp - 1000 mg available white off-white , oval shaped , biconvex , coated tablets debossed ‘ m1000 ’ one face plain face approximate dimension 20.10mm length , 11.40 mm width 8.50 mm thickness . supplied follows : bottle 60 ’ ndc 42571-334-60 bottle 90 ’ ndc 42571-334-90 bottle 100 ’ ndc 42571-334-01 bottle 500 ’ ndc 42571-334-05 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . preserve well-closed , light-resistant containers .",
    "adverseReactions": "metformin hydrochloride extended-release tablets contraindicated patients : severe renal impairment ( egfr 30 ml/minute/1.73 2 ) [ ( 5.1 ) ] . known hypersensitivity metformin . acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma .",
    "indications_original": "Metformin hydrochloride extended-release tablet  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications_original": "Starting dose: 500 mg orally once daily with the evening meal ( 2.1 ) Increase the dose in increments of 500 mg every 1 to 2 weeks, up to a maximum of 2,000 mg once daily with the evening meal. ( 2.1 ) Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. ( 2.1 ) Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 . Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 . Assess risk/benefit of continuing metformin hydrochloride extended-release tablets if eGFR falls below 45 mL/minute/1.73 m 2 . Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 . Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.3 )",
    "warningsAndPrecautions_original": "Metformin hydrochloride extended-release tablets, USP - 500 mg are available as blue colored oval shaped biconvex, film-coated, tablets debossed with ‘M500’ on one face and plain on other face with an approximate dimension of 16.20 mm length, 8.20 mm width and 7.20 mm thickness.\n                  \n                  They are supplied as follows:\n                  \n                  Bottle of 60’s                                                                          NDC 42571-333-60\n                  Bottle of 90’s                                                                          NDC 42571-333-90\n                  Bottle of 100’s                                                                        NDC 42571-333-01\n                  Bottle of 500’s                                                                        NDC 42571-333-05\n                  \n                  \n                  Metformin hydrochloride extended-release tablets, USP - 1000 mg are available as white to off-white, oval shaped, biconvex, coated tablets debossed with ‘M1000’ on one face and plain on other face with an approximate dimension of 20.10mm length, 11.40 mm width and 8.50 mm thickness.\n                  \n                  They are supplied as follows:\n                  Bottle of 60’s                                                                          NDC 42571-334-60\n                  Bottle of 90’s                                                                          NDC 42571-334-90\n                  Bottle of 100’s                                                                        NDC 42571-334-01\n                  Bottle of 500’s                                                                        NDC 42571-334-05\n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. \n  \n                       Preserve in well-closed, light-resistant containers.",
    "adverseReactions_original": "Metformin hydrochloride extended-release tablets are contraindicated in patients with:\n                  \n                  \n                     Severe renal impairment (eGFR below 30 mL/minute/1.73 m\n  \n   2)\n  \n   [see\n                        \n                           Warnings and Precautions ( 5.1 )].\n  \n   \n                     \n                     Known hypersensitivity to metformin.\n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma."
}